Nuvation Bio Inc. NUVB
4.16 USD -0.13 (-3.15%)
Nov 12, 2026, 9:55 AM EST
4.14 Day range 4.22
3.98 52-week range 9.75
- YTD
- -53.63%
- 1 year
- -15.72%
News
prnewswire.com Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David…
seekingalpha.com Nuvation Bio: The Market Is Counting New Starts While IBTROZI Stacks Patients Nuvation Bio's Ibtrozi's roughly 50-month first-line durability means revenue depends on patients staying on therapy, not just new starts. Q3 Ibtrozi revenue rose 18% sequentially to $27.5 million,…
marketbeat.com What Nuvation Bio (NUVB) Said on Its Q3 Earnings Call Nuvation Bio NYSE: NUVB reported $45 million in third-quarter 2026 revenue as U.S. sales of lung cancer treatment IBTROZI rose 18% from the previous quarter, even as the company said new patient…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.
benzinga.com RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $17 RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $20 to $17.
benzinga.com Nuvation Bio Q3 2026 Earnings Call Transcript Nuvation Bio (NYSE:NUVB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…
benzinga.com Nuvation Bio Q3 EPS $(0.12), Inline, Sales $44.951M Beat $34.224M Estimate Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(0.16) per share from the same period…
benzinga.com Nuvation Bio To Present Updated Data From Its Phase 2 J201 Trial, Three Posters On Ongoing Studies Of Safusidenib At Society For Neuro-Oncology Annual Meeting Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional updated results from the Phase 2…
benzinga.com Nuvation Bio Plans To Add Sites In Six European Countries For Its Pivotal Phase 3 SIGMA Study Of Safusidenib Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the pivotal Phase 3 SIGMA (G203; NCT05303519)…
benzinga.com This Ciena Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiated coverage: Buy on FORM ($200), NUVB ($12); Outperform on CIEN ($440); Neutral on EXPD ($180); Equal-Weight on SFD ($22).
benzinga.com Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12 Citigroup analyst Geoff Meacham initiates coverage on Nuvation Bio (NYSE:NUVB) with a Buy rating and announces Price Target of $12.
benzinga.com Why Is Nuvation Bio Stock Gaining Thursday? Nuvation Bio (NUVB) stock jumps 6% after early FDA label update for IBTROZI, highlighting over 4 years of clinical benefit in ROS1+ NSCLC.
benzinga.com Nuvation Bio Says FDA Approves sNDA For IBTROZI, ROS1 Inhibitor For Treatment Of Locally Advanced Or Metastatic ROS1-Positive Non-Small Cell Lung Cancer Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 monthsNo changes to the safety sections of labeling with longer follow-up and no new safety signals…- benzinga.com Citizens Reiterates Market Outperform on Nuvation Bio, Maintains $10 Price Target Citizens analyst Silvan Turkcan reiterates Nuvation Bio (NYSE:NUVB) with a Market Outperform and maintains $10 price target.
- benzinga.com Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.
- benzinga.com Nuvation Bio Announces New Subgroup Analyses From Pivotal TRUST-I And TRUST-II Studies Evaluating IBTROZI In Both TKI- Naïve And TKI-Pretreated Patients With Advanced ROS1+ NSCLC Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1…
benzinga.com Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is... Cramer calls Nuvation Bio a pure spec, prefers CoreWeave over IREN, is unsure on Seneca, cautious on NuScale, and approves Box.
benzinga.com This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings page. TER, TX and more.
benzinga.com This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Wall Street analysts upgraded Parsons Corp, InnovAge Holding Corp, Equifax Inc, and initiated coverage on Builders FirstSource, Inc and Nuvation Bio Inc.
benzinga.com This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.- benzinga.com Nuvation Bio Says FDA Grants Fast Track Designation For Safusidenib, Investigational, Oral, Brain-Penetrant Selective Inhibitor Of Mutant IDH1 Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant…
- benzinga.com JP Morgan Initiates Coverage On Nuvation Bio with Overweight Rating, Announces Price Target of $13 JP Morgan analyst Priyanka Grover initiates coverage on Nuvation Bio (NYSE:NUVB) with a Overweight rating and announces Price Target of $13.
benzinga.com RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $20 RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $19 to $20.
benzinga.com Nuvation Bio Q2 EPS $(0.18) Beats $(0.19) Estimate, Sales $31.687M Beat $27.505M Estimate Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 5.88 percent decrease over losses of $(0.17)…- benzinga.com Nuvation Bio Announces New Subgroup Analyses Of Phase 2 TRUST-I And TRUST-II Data For IBTROZI In ROS1+ NSCLC Will Be Presented At WCLC And ESMO Presentations Overview:WCLCTitle: Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From TRUST-I and TRUST-IIPresenter: Hidetoshi Hayashi, Kindai…
benzinga.com HC Wainwright & Co. Maintains Buy on Nuvation Bio, Raises Price Target to $21 HC Wainwright & Co. analyst Robert Burns maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises the price target from $17 to $21.- benzinga.com Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.
benzinga.com Why Is Nuvation Bio Stock Gaining Monday? Nuvation Bio reports positive long-term Phase 2 safusidenib data for glioma patients and expands its clinical trial pipeline.
benzinga.com AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On Monday U.S. stocks saw mixed results, with Nasdaq up 150 points. AMC shares rose after beating earnings expectations. Other big gainers include NUAI, IREN, XNCR, HUT, CIFR, CLSK, NUVB, AXTI, ATEX, APLD, and…- benzinga.com Nuvation Bio Announces Positive Updated Phase 2 Data And Expansion From Safusidenib Clinical Trial In Newly-Diagnosed Grade 2 Glioma Patients Outside The U.S. Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-upNew Phase 3 study to evaluate…
- benzinga.com RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $19 RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $20 to $19.
- benzinga.com Truist Securities Maintains Buy on Nuvation Bio, Raises Price Target to $13 Truist Securities analyst Gregory Renza maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises the price target from $12 to $13.
benzinga.com H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release and offer to acquire Advanced Medical Solutions.- benzinga.com Nuvation Bio Intends To Offer $200M Aggregate Principal Amount Of Convertible Senior Notes Due In 2032 Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to…
- benzinga.com Nuvation Bio To Showcase New Outcomes Data From Its Pivotal TRUST-II Trial Of IBTROZI In Participants With Advanced ROS1-Positive Non-Small Cell Lung Cancer Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new patient-reported outcomes data from the pivotal…
- benzinga.com RBC Capital Reiterates Outperform on Nuvation Bio, Maintains $20 Price Target RBC Capital analyst Leonid Timashev reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $20 price target.
- benzinga.com Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $17 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $17 price target.
benzinga.com Nuvation Bio Q1 EPS $0.01, Inline, Sales $83.228M Beat $62.259M Estimate. Nuvation Bio (NYSE:NUVB) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. This is a 106.25 percent increase over losses of $(0.16) per share from the same…
benzinga.com Earnings Scheduled For May 4, 2026 - benzinga.com Nuvation Bio Reveals IBTROZI Showed Highly Durable Responses in Longer-Term Follow-Up Data From Pivotal Studies Presented At AACR 2026; IBTROZI Also Demonstrated A High Overall Response Rate In TKI-Naïve Patients At 89.8%; Preclinical Data Presented At AACR Showed Taletrectinib's Potential For Suppressing TrkB-mediated Lung Cancer Cell Migration Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced results from a pooled analysis of long-term follow-up…
- benzinga.com Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.
- benzinga.com Nuvation Bio Amends Current License Deal With Daiichi Sankyo For Safusidenib To Add Japan Rights Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the company has amended its existing exclusive…
- benzinga.com Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.
- benzinga.com Eisai, Nuvation Bio Announces European Medicines Agency Validate Marketing Authorisation Application For Taletrectinib To Treat ROS1-Positive Non-Small Cell Lung Cancer Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and…
- benzinga.com Nuvation Bio Reports IBTROZI Achieves 50-Month Median Response In ROS1+ NSCLC, To Be Presented At AACR 2026 Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) now increased to 50…
benzinga.com Deep Dive Into Nuvation Bio Stock: Analyst Perspectives (7 Ratings) - benzinga.com UBS Maintains Neutral on Nuvation Bio, Lowers Price Target to $7 UBS analyst Michael Yee maintains Nuvation Bio (NYSE:NUVB) with a Neutral and lowers the price target from $10 to $7.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $13 RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $12 to $13.